# Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and Genomics

> **NCT06295029** · — · NOT_YET_RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 200 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06295029
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06295029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06295029, "Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and Genomics". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06295029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*